Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958880 · ClinicalTrials.gov registry record · Phase 3
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
A Phase 3 study of Social Anxiety Disorder, sponsored by Southern Methodist University.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT00958880: Completed Phase 3 study of Social Anxiety Disorder, sponsored by Southern Methodist University.
NCT00958880 is a Phase 3 study of Social Anxiety Disorder that has completed, run by Southern Methodist University. The registered enrollment target is 40 participants, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00958880, a Phase 3 study of Social Anxiety Disorder, has completed, sponsored by Southern Methodist University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to investigate the utility of Yohimbine hydrochloride for facilitating fear extinction in a sample of patients with social phobia who will be treated with CBT.
Primary Outcome
The Liebowitz Social Anxiety Scale (LSAS) is a self-report measure of social anxiety symptom severity. Scores range from 0 to 144, with higher scores indicating more social anxiety symptoms severity (i.e., a worse outcome).
Conditions Studied
Interventions
- DRUG Yohimbine Hydrochloride
- DRUG Sugar Pill
- BEHAVIORAL Group Cognitive Behavioral Therapy
Study Locations (2)
Massachusetts
- Boston University - Boston
Texas
- Southern Methodist University - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
What the finished NCT00958880 record still lists
NCT00958880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which Yohimbine Hydrochloride is the first listed.
NCT00958880 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT00958880 about?
NCT00958880 is a clinical study titled "Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety". The purpose of this study is to investigate the utility of Yohimbine hydrochloride for facilitating fear extinction in a sample of patients with social phobia who will be treated with CBT.
What is the current status of trial NCT00958880?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2009-03. Estimated completion is 2013-01.
What conditions does trial NCT00958880 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT00958880?
The interventions under investigation include: Yohimbine Hydrochloride (DRUG), Sugar Pill (DRUG), Group Cognitive Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00958880?
This trial is sponsored by Southern Methodist University, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00958880 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00958880's enrollment target sits among peer trials
40 29th of 32 the lowest of 32 other Social Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
COMPLETED · Phase 3
-
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia